Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

A new report paints a grim outlook for the Massachusetts biotech industry, as venture investment fell 17% in the first half ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

A Philadelphia biotech startup's promising approach to cancer therapy is about to get the firm acquired by a major player in ...

AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major ...

In a comparison of revenue and earnings, Gilead wins again. Last year, the biotech generated earnings of $12.1 billion on revenue of $24.9 billion.

Gilead Sciences, Inc. GILD and Bristol Myers Squibb BMY are leading biotechnology companies with broad and diverse portfolios and a global footprint. Gilead Sciences is a pioneer in developing ...

Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats, according to analysts. Read more here.

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.